The acquisition of a passive stake by Bio-Rad Laboratories in Oncocyte Corp suggests a strategic interest but does not imply immediate operational changes or control over Oncocyte. This move could be seen as a positive endorsement of OCX's potential, but since it's a passive investment, the immediate impact on BIO's stock might be neutral. Investors will view this as a long-term interest rather than a short-term performance driver.

The acquisition of a passive stake by a reputable firm like Bio-Rad Laboratories could be perceived positively by the market, reflecting a vote of confidence in Oncocyte Corp's future prospects. This could lead to a short-term positive sentiment among investors, potentially boosting OCX's stock price. However, as the stake is passive, it might not lead to immediate material changes in the company's operations or strategic direction.